Institution
New York University
Education•New York, New York, United States•
About: New York University is a education organization based out in New York, New York, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 72380 authors who have published 165545 publications receiving 8334030 citations. The organization is also known as: NYU & University of the City of New York.
Topics: Population, Poison control, Context (language use), Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
23 Oct 2005TL;DR: A simple, inexpensive, and scalable technique for enabling high-resolution multi-touch sensing on rear-projected interactive surfaces based on frustrated total internal reflection is described.
Abstract: This paper describes a simple, inexpensive, and scalable technique for enabling high-resolution multi-touch sensing on rear-projected interactive surfaces based on frustrated total internal reflection. We review previous applications of this phenomenon to sensing, provide implementation details, discuss results from our initial prototype, and outline future directions.
1,151 citations
•
TL;DR: It is shown that cultural transmission mechanisms have very different implications than evolutionary selection mechanisms with respect to the dynamics of the distribution of the traits in the population, and mechanisms which interact evolutionary selection and cultural transmission are studied.
Abstract: This paper studies the population dynamics of preference traits in a model of intergenerational cultural transmission. Parents socialize and transmit their preferences to their offspring, motivated by a form of paternalistic altruism (“imperfect empathy”). In such a setting we study the long run stationary state pattern of preferences in the population, according to various socialization mechanisms and institutions, and identify sufficient conditions for the global stability of an heterogenous stationary distribution of the preference traits. We show that cultural transmission mechanisms have very different implications than evolutionary selection mechanisms with respect to the dynamics of the distribution of the traits in the population, and we study mechanisms which interact evolutionary selection and cultural transmission. Journal of Economic Literature Classification numbers: D10, I20, J13.
1,151 citations
••
TL;DR: It is demonstrated that although chronic suppression of HIV-1 permits near-complete immune recovery of the peripheral blood CD4+ T cell population, a significantly greater CD4- T cell loss remains in the GI mucosa, despite up to 5 yr of fully suppressive therapy.
Abstract: Given its population of CCR5-expressing, immunologically activated CD4+ T cells, the gastrointestinal (GI) mucosa is uniquely susceptible to human immunodeficiency virus (HIV)-1 infection. We undertook this study to assess whether a preferential depletion of mucosal CD4+ T cells would be observed in HIV-1–infected subjects during the primary infection period, to examine the anatomic subcompartment from which these cells are depleted, and to examine whether suppressive highly active antiretroviral therapy could result in complete immune reconstitution in the mucosal compartment. Our results demonstrate that a significant and preferential depletion of mucosal CD4+ T cells compared with peripheral blood CD4+ T cells is seen during primary HIV-1 infection. CD4+ T cell loss predominated in the effector subcompartment of the GI mucosa, in distinction to the inductive compartment, where HIV-1 RNA was present. Cross-sectional analysis of a cohort of primary HIV-1 infection subjects showed that although chronic suppression of HIV-1 permits near-complete immune recovery of the peripheral blood CD4+ T cell population, a significantly greater CD4+ T cell loss remains in the GI mucosa, despite up to 5 yr of fully suppressive therapy. Given the importance of the mucosal compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes observed here is critical.
1,150 citations
••
TL;DR: The X-ray structure of the Mucor miehei triglyceride lipase is reported and the atomic model obtained reveals a Ser .. His .. Asp trypsin-like catalytic triad with an active serine buried under a short helical fragment of a long surface loop.
Abstract: True lipases attach triacylglycerols and act at an oil-water interface; they constitute a ubiquitous group of enzymes catalysing a wide variety of reactions, many with industrial potential. But so far the three-dimensional structure has not been reported for any lipase. Here we report the X-ray structure of the Mucor miehei triglyceride lipase and describe the atomic model obtained at 3.1 A resolution and refined to 1.9 A resolution. It reveals a Ser..His..Asp trypsin-like catalytic triad with an active serine buried under a short helical fragment of a long surface loop.
1,149 citations
••
TL;DR: Bivalirudin with provisional Gp IIb/IIIa blockade is statistically not inferior to heparin plus planned Gp IIIa blockade during contemporary PCI with regard to suppression of acute ischemic end points and is associated with less bleeding.
Abstract: ContextThe direct thrombin inhibitor bivalirudin has been associated with better
efficacy and less bleeding than heparin during coronary balloon angioplasty
but has not been widely tested during contemporary percutaneous coronary intervention
(PCI).ObjectiveTo determine the efficacy of bivalirudin, with glycoprotein IIb/IIIa
(Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI,
compared with heparin plus planned Gp IIb/IIIa blockade with regard to protection
from periprocedural ischemic and hemorrhagic complications.Design, Setting, and ParticipantsThe Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical
Events (REPLACE)–2 trial, a randomized, double-blind, active-controlled
trial conducted among 6010 patients undergoing urgent or elective PCI at 233
community or referral hospitals in 9 countries from October 2001 through August
2002.InterventionsPatients were randomly assigned to receive intravenous bivalirudin (0.75-mg/kg
bolus plus 1.75 mg/kg per hour for the duration of PCI), with provisional
Gp IIb/IIIa inhibition (n = 2999), or heparin (65-U/kg bolus) with planned
Gp IIb/IIIa inhibition (abciximab or eptifibatide) (n = 3011). Both groups
received daily aspirin and a thienopyridine for at least 30 days after PCI.Main Outcome MeasuresThe primary composite end point was 30-day incidence of death, myocardial
infarction, urgent repeat revascularization, or in-hospital major bleeding;
the secondary composite end point was 30-day incidence of death, myocardial
infarction, or urgent repeat revascularization.ResultsProvisional Gp IIb/IIIa blockade was administered to 7.2% of patients
in the bivalirudin group. By 30 days, the primary composite end point had
occurred among 9.2% of patients in the bivalirudin group vs 10.0% of patients
in the heparin-plus-Gp IIb/IIIa group (odds ratio, 0.92; 95% confidence interval,
0.77-1.09; P = .32). The secondary composite end
point occurred in 7.6% of patients in the bivalirudin vs 7.1% of patients
in the heparin-plus-Gp IIb/IIIa groups (odds ratio, 1.09; 95% confidence interval
0.90-1.32; P = .40). Prespecified statistical criteria
for noninferiority to heparin plus Gp IIb/IIIa were satisfied for both end
points. In-hospital major bleeding rates were significantly reduced by bivalirudin
(2.4% vs 4.1%; P<.001).ConclusionsBivalirudin with provisional Gp IIb/IIIa blockade is statistically not
inferior to heparin plus planned Gp IIb/IIIa blockade during contemporary
PCI with regard to suppression of acute ischemic end points and is associated
with less bleeding.
1,148 citations
Authors
Showing all 73237 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rob Knight | 201 | 1061 | 253207 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Frank E. Speizer | 193 | 636 | 135891 |
Stephen V. Faraone | 188 | 1427 | 140298 |
Eric R. Kandel | 184 | 603 | 113560 |
Andrei Shleifer | 171 | 514 | 271880 |
Eliezer Masliah | 170 | 982 | 127818 |
Roderick T. Bronson | 169 | 679 | 107702 |
Timothy A. Springer | 167 | 669 | 122421 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
Nora D. Volkow | 165 | 958 | 107463 |
Dennis R. Burton | 164 | 683 | 90959 |
Charles N. Serhan | 158 | 728 | 84810 |
Giacomo Bruno | 158 | 1687 | 124368 |
Tomas Hökfelt | 158 | 1033 | 95979 |